Double-Blind Therapeutic Trial in Angelman Syndrome Using Betaine and Folic Acid

作者：Peters Sarika U; Bird Lynne M; Kimonis Virginia; Glaze Daniel G; Shinawi Una M; Bichell Terry Jo; Barbieri Welge Rene; Nespeca Mark; Anselm Irina; Wai**ren Susan; Sanborn Erica; Sun Qin; O'Brien William E; Beaudet Arthur L; Bacino Carlos A^*

来源：American Journal of Medical Genetics, Part A, 2010, 152A(8): 1994-2001.

DOI：10.1002/ajmg.a.33509

• Angelman syndrome
• methylation
• high dose folic acid
• betaine
• imprinting disorders
• treatment
• promotion of methylation

Angelman syndrome (AS) is caused by reduced or absent expression of the maternally inherited ubiquitin protein ligase 3A gene (UBE3A), which maps to chromosome 15q11 q13. UBE3A is subject to genomic imprinting in neurons in most regions of the brain. Expression of UBE3A from the maternal chromosome is essential to prevent AS, because the paternally inherited gene is not expressed, probably mediated by antisense UBE3A RNA. We hypothesized that increasing methylation might reduce expression of the antisense UBE3A RNA, thereby increasing UBE3A expression from the paternal gene and ameliorating the clinical phenotype. We conducted a trial using two dietary supplements, betaine and folic acid to promote global levels of methylation and attempt to activate the paternally inherited UBE3A gene. We performed a number of investigations at regular intervals including general clinical and developmental evaluations, biochemical determinations on blood and urine, and electroencephalographic studies. We report herein the data on 48 children with AS who were enrolled in a double-blind placebo-controlled protocol using betaine and folic acid for 1 year. There were no statistically significant changes between treated and untreated children; however, in a small subset of patients we observed some positive trends.

• 出版日期2010-8